Woodline Partners LP Sells 12,183 Shares of Kymera Therapeutics, Inc. $KYMR

Key Points

• Woodline Partners LP has reduced its stake in Kymera Therapeutics, Inc. by 2.3%, holding 525,245 shares worth approximately $14.38 million as of their latest SEC filing.
• Kymera Therapeutics reported a significant earnings miss for the last quarter, with a loss of ($0.95) per share, underperforming against the consensus estimate of ($0.83).
• Analysts hold a generally positive outlook on Kymera, with a majority rating it as "Buy" and setting an average price target of $58.76, indicating potential upward movement in the stock price.

Woodline Partners LP cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 2.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 525,245 shares of the company's stock after selling 12,183 shares during the period. Woodline Partners LP owned about 0.81% of Kymera Therapeutics worth $14,376,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of KYMR. Northern Trust Corp boosted its stake in Kymera Therapeutics by 14.0% in the fourth quarter. Northern Trust Corp now owns 437,833 shares of the company's stock valued at $17,614,000 after acquiring an additional 53,658 shares during the period. Ameriprise Financial Inc. acquired a new position in shares of Kymera Therapeutics during the fourth quarter valued at $344,000. BNP Paribas Financial Markets acquired a new position in shares of Kymera Therapeutics during the fourth quarter valued at $396,000. Deutsche Bank AG boosted its holdings in shares of Kymera Therapeutics by 65.7% during the fourth quarter. Deutsche Bank AG now owns 72,442 shares of the company's stock valued at $2,914,000 after acquiring an additional 28,726 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in shares of Kymera Therapeutics by 2,397.9% during the fourth quarter. Janus Henderson Group PLC now owns 377,384 shares of the company's stock valued at $15,197,000 after acquiring an additional 362,276 shares during the period.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Bvf Partners L. P/Il purchased 317,167 shares of the firm's stock in a transaction that occurred on Monday, June 30th. The shares were acquired at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the transaction, the director directly owned 2,798,795 shares in the company, valued at approximately $123,146,980. The trade was a 12.78% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Bros. Advisors Lp Baker purchased 655,500 shares of the firm's stock in a transaction that occurred on Monday, June 30th. The shares were acquired at an average price of $44.00 per share, for a total transaction of $28,842,000.00. Following the completion of the transaction, the director owned 6,117,295 shares in the company, valued at $269,160,980. The trade was a 12.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. 16.01% of the stock is owned by corporate insiders.

Kymera Therapeutics Stock Up 2.8%

NASDAQ:KYMR traded up $1.33 during trading hours on Tuesday, reaching $48.61. The company had a trading volume of 264,409 shares, compared to its average volume of 732,681. The stock has a 50-day moving average of $43.47 and a two-hundred day moving average of $37.45. Kymera Therapeutics, Inc. has a one year low of $19.44 and a one year high of $53.27. The firm has a market capitalization of $3.48 billion, a PE ratio of -13.96 and a beta of 2.17.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The firm had revenue of $11.48 million for the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.Kymera Therapeutics's quarterly revenue was down 55.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.58) earnings per share. As a group, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. BTIG Research reiterated a "buy" rating and set a $59.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 26th. Morgan Stanley initiated coverage on Kymera Therapeutics in a research report on Thursday, July 3rd. They set an "overweight" rating and a $70.00 price target for the company. Wells Fargo & Company reduced their price objective on shares of Kymera Therapeutics from $57.00 to $53.00 and set an "overweight" rating for the company in a report on Thursday, June 26th. Bank of America raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price objective for the company in a report on Monday, June 2nd. Finally, Oppenheimer reaffirmed an "outperform" rating and issued a $53.00 price target (down from $56.00) on shares of Kymera Therapeutics in a research note on Friday, June 27th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Kymera Therapeutics currently has a consensus rating of "Buy" and an average price target of $59.39.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.